- Home
- SYRE
as 03-28-2025 4:00pm EST
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.2B | IPO Year: | 2016 |
| Target Price: | $51.50 | AVG Volume (30 days): | 664.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.71 - $40.84 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -95.97% |
Latest Spyre Therapeutics Inc. News
SYRE Breaking Stock News: Dive into SYRE Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
PR Newswire
22 days ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
a month ago
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
PR Newswire
a month ago
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
PR Newswire
2 months ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
3 months ago
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
PR Newswire
3 months ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
3 months ago
Spyre Therapeutics Added to the Nasdaq Biotechnology Index
Compare SYRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SYRE Spyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.